CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 50 enrolled
Drug / intervention
Memantinedrug
Likely dose
Memantine 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00652457
NCT00652457Phase 4Completed
CompareCT.gov

A Pilot Study of Memantine for Cognitive and Behavioral Dysfunction in Huntington's Disease"

Jody Corey-Bloom, MD, PhD·interventional·Posted Apr 3, 2008·Updated Jan 5, 2021

In Brief

A Phase 4 clinical trial evaluating Memantine for Huntington's Disease. Completed, enrolled 50 participants across 3 sites.

Detailed Summary

To determine if memantine in doses of 10 mg BID affects memory, cognition, and behavior in patients with Huntington's disease (HD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuntington's Disease
CountriesUnited States
CollaboratorsForest Laboratories

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 3, 2008
Enrollment StartNov 23, 2004
Primary CompletionOct 28, 2009
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 18.2 years ago

Interventions

Memantinedrug

10 mg BID x 3 months